AR033378A1 - Derivado de antigeno de prostasa, secuencia de acido nucleico que lo codifica, vector de expresion que contiene al anterior, celula huesped transformada con dicha secuencia de a cido nucleico o dicho vector , vacuna que comprende al derivado de antigeno o a la secuencia de acido nucleico, uso del de - Google Patents

Derivado de antigeno de prostasa, secuencia de acido nucleico que lo codifica, vector de expresion que contiene al anterior, celula huesped transformada con dicha secuencia de a cido nucleico o dicho vector , vacuna que comprende al derivado de antigeno o a la secuencia de acido nucleico, uso del de

Info

Publication number: AR033378A1
Authority: AR; Argentina
Prior art keywords: protein; nucleic acid; prostase; vaccines; sequence
Prior art date: 2000-06-27

Application number

ARP010103045A

Other languages

English (en)

Spanish (es)

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-27

Filing date

2001-06-26

Publication date

2003-12-17

2001-06-26 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

2003-12-17 Publication of AR033378A1 publication Critical patent/AR033378A1/es

Links

150000007523 nucleic acids Chemical group 0.000 title abstract 8
102100034872 Kallikrein-4 Human genes 0.000 title abstract 6
108010024383 kallikrein 4 Proteins 0.000 title abstract 6
229960005486 vaccine Drugs 0.000 title abstract 6
108091028043 Nucleic acid sequence Proteins 0.000 title abstract 4
239000000427 antigen Substances 0.000 title abstract 4
102000036639 antigens Human genes 0.000 title abstract 4
108091007433 antigens Proteins 0.000 title abstract 4
102000039446 nucleic acids Human genes 0.000 title abstract 4
108020004707 nucleic acids Proteins 0.000 title abstract 4
239000013598 vector Substances 0.000 title abstract 3
210000000988 bone and bone Anatomy 0.000 title 1
235000018102 proteins Nutrition 0.000 abstract 8
102000004169 proteins and genes Human genes 0.000 abstract 8
108090000623 proteins and genes Proteins 0.000 abstract 8
230000004927 fusion Effects 0.000 abstract 5
239000002671 adjuvant Substances 0.000 abstract 3
238000004519 manufacturing process Methods 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
230000035772 mutation Effects 0.000 abstract 2
102000019034 Chemokines Human genes 0.000 abstract 1
108010012236 Chemokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
239000004698 Polyethylene Substances 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
150000002170 ethers Chemical class 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
206010022000 influenza Diseases 0.000 abstract 1
239000007764 o/w emulsion Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
-1 polyethylene Polymers 0.000 abstract 1
229920000573 polyethylene Polymers 0.000 abstract 1
150000003573 thiols Chemical class 0.000 abstract 1
230000001131 transforming effect Effects 0.000 abstract 1
239000007762 w/o emulsion Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

ARP010103045A 2000-06-27 2001-06-26 Derivado de antigeno de prostasa, secuencia de acido nucleico que lo codifica, vector de expresion que contiene al anterior, celula huesped transformada con dicha secuencia de a cido nucleico o dicho vector , vacuna que comprende al derivado de antigeno o a la secuencia de acido nucleico, uso del de AR033378A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0015736.2A GB0015736D0 (en)	2000-06-27	2000-06-27	Vaccine

Publications (1)

Publication Number	Publication Date
AR033378A1 true AR033378A1 (es)	2003-12-17

Family

ID=9894505

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP010103045A AR033378A1 (es)	2000-06-27	2001-06-26	Derivado de antigeno de prostasa, secuencia de acido nucleico que lo codifica, vector de expresion que contiene al anterior, celula huesped transformada con dicha secuencia de a cido nucleico o dicho vector , vacuna que comprende al derivado de antigeno o a la secuencia de acido nucleico, uso del de

Country Status (4)

Country	Link
AR (1)	AR033378A1 (fr)
AU (1)	AU2001285773A1 (fr)
GB (1)	GB0015736D0 (fr)
WO (1)	WO2002000708A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5786148A (en) *	1996-11-05	1998-07-28	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding a novel prostate-specific kallikrein
US5955306A (en) *	1996-09-17	1999-09-21	Millenium Pharmaceuticals, Inc.	Genes encoding proteins that interact with the tub protein
DE19805633A1 (de) *	1998-02-12	1999-08-19	Basf Ag	Neue Serinprotease aus der Prostata
TR200100916T2 (fr) *	1998-07-14	2002-06-21	Corixa@@Corporation
JP2003504080A (ja) *	1999-07-13	2003-02-04	スミスクラインビーチャムバイオロジカルズソシエテアノニム	ワクチン

2000
- 2000-06-27 GB GBGB0015736.2A patent/GB0015736D0/en not_active Ceased
2001
- 2001-06-21 WO PCT/EP2001/007079 patent/WO2002000708A2/fr not_active Ceased
- 2001-06-21 AU AU2001285773A patent/AU2001285773A1/en not_active Abandoned
- 2001-06-26 AR ARP010103045A patent/AR033378A1/es unknown

Also Published As

Publication number	Publication date
GB0015736D0 (en)	2000-08-16
WO2002000708A3 (fr)	2002-05-16
WO2002000708A2 (fr)	2002-01-03
AU2001285773A1 (en)	2002-01-08

Legal Events

Date	Code	Title	Description
2004-09-06	FB	Suspension of granting procedure

Publication	Publication Date	Title
US12442005B2 (en)	2025-10-14	Artificial nucleic acid molecules for improved protein expression
US11254951B2 (en)	2022-02-22	Artificial nucleic acid molecules
US20260000749A1 (en)	2026-01-01	Rotavirus vaccines
Van Lint et al.	2015	The ReNAissanCe of mRNA-based cancer therapy
US10047375B2 (en)	2018-08-14	Artificial nucleic acid molecules
BR112021024786A2 (pt)	2022-02-22	Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
US20180148727A1 (en)	2018-05-31	Artificial nucleic acid molecules
CN113164584A (zh)	2021-07-23	免疫原性组合物及其用途
CL2019003405A1 (es)	2020-03-27	Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
WO2023049636A3 (fr)	2023-08-03	Compositions de thérapie anticancéreuse et leurs utilisations
CO5580165A1 (es)	2005-11-30	Vacunas de rotavirus modificado
BR0213941A (pt)	2004-08-31	Arranjos de antìgeno para o tratamento de doença óssea
CN119633108B (zh)	2025-12-09	基于细胞焦亡诱导的mRNA疫苗佐剂及其应用
MX2024015396A (es)	2025-02-10	Anticuerpo y su uso
Ankrah et al.	2023	Clinical analysis and applications of mRNA vaccines in infectious diseases and cancer treatment
FR2746110B1 (fr)	1998-04-17	Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
PE20242221A1 (es)	2024-11-19	Antigenos tumorales, compuestos que comprenden los antigenos tumorales kras, tpx2 o aurka y usos de los mismos
Guo et al.	2025	Double-metal ion adjuvant stabilized Pickering emulsion to amplify humoral and cellular immune responses
Tan et al.	2022	Circular RNA vaccines against SARS-CoV-2 and emerging variants
Luo et al.	2026	Developing a Next-Generation Vaccine Adjuvant System through Rational Design to Alleviate AS01 Adjuvant Deficiency
WO2001030989A3 (fr)	2001-11-22	Procede de creation de populations divergentes de molecules et de proteines d'acide nucleique
HK40077948A (en)	2023-03-24	Artificial nucleic acid molecules for improved protein expression
HK40077948B (en)	2023-09-08	Artificial nucleic acid molecules for improved protein expression
WO2024151583A3 (fr)	2024-11-07	Vaccins et procédés associés
MX2024012254A (es)	2024-11-08	Vacunas y metodos relacionados